Early Detection of Simian Immunodeficiency Virus in the Central Nervous System Following Oral Administration to Rhesus Macaques by Jeffrey M. Milush et al.
ORIGINAL RESEARCH ARTICLE
published: 14 August 2013
doi: 10.3389/fimmu.2013.00236
Early detection of simian immunodeficiency virus in the
central nervous system following oral administration to
rhesus macaques
Jeffrey M. Milush1, Hui-Ling Chen2, Ginger Atteberry 3† and Donald L. Sodora2*
1 Department of Medicine, Division of Experimental Medicine, University of California San Francisco, San Francisco, CA, USA
2 Seattle Biomedical Research Institute, Seattle, WA, USA
3 Southwestern Medical Center, University of Texas, Dallas, TX, USA
Edited by:
Annapurna Vyakarnam, King’s College
London, UK
Reviewed by:
Annapurna Vyakarnam, King’s College
London, UK
Kelly Stefano Cole, University of
Pittsburgh, USA
*Correspondence:
Donald L. Sodora, Seattle Biomedical
Research Institute, 307 Westlake




Ginger Atteberry , Battelle Contractor,
Influenza Division, Virus Surveillance
and Diagnostic Branch, NCIRD, CCID,
Centers for Disease Control and
Prevention, Atlanta, GA, USA
The timing of HIV dissemination to the central nervous system (CNS) has the potential to
have important implications regarding HIV disease progression and treatment. The earlier
HIV enters the CNS the more difficult it might be to remove with antiretroviral therapy.
Alternatively, HIV may only enter the CNS later in the course of disease as a result of
disruption of the blood-brain-barrier. We utilized the simian immunodeficiency virus (SIV)
infection of rhesus macaques to evaluate the oral route of infection and the subsequent
spread of SIV to the CNS during the acute infection phase. A high dose oral SIV challenge
was utilized to ensure a successful infection and permit the evaluation of CNS spread dur-
ing the first 1–14 days post-infection. Ultrasensitive nested PCR was used to detect SIV
gag DNA in the brains of macaques at 1–2 days post-infection and identified SIV gag DNA
in the brain tissues from three of four macaques.This SIV DNA was also present following
perfusion of the macaque brains, providing evidence that it was not residing in the circu-
lating blood but in the brain tissue itself. The diversity of the viral envelope V1–V2 region
at early times post-infection indicated that the brain viral variants were similar to variants
obtained from lymph nodes. This genetic similarity between SIV obtained from lymphoid
and brain tissues suggests that the founder population of viral species entered and sub-
sequently spread without any evidence of brain-specific SIV selection. The relatively rapid
appearance of SIV within the CNS tissue following oral transmission may also occur during
HIV transmission where it may impact disease course as well as representing a challenge
for long-term therapies and future viral eradication modalities.
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INTRODUCTION
HIV-associated neurologic disorders generally do not manifest
themselves until onset of AIDS when the clinical disease can be
readily observed (1). Recently, insights into HIV-induced central
nervous system (CNS) abnormalities have been revealed utiliz-
ing magnetic resonance imaging (MRI). Functional MRI studies
have determined that structural changes in the brains of HIV-
infected persons are similar to the effects of aging in HIV-negative
people (2, 3). Furthermore, alterations in brain metabolites in
patients exhibiting AIDS dementia complex (ADC) have identi-
fied a decrease in the ratio of acetylaspartate to creatine in both the
gray and white matter (4–6). Changes could also be observed in
HIV-infected patients without ADC including an increase in the
ratio of myo-inositol to creatine in white matter (2, 5, 6). There-
fore, although the clinical manifestations of ADC occur during the
onset of AIDS, evidence suggests that the virus has been present
and inducing changes in the CNS prior to end stage disease signs
(7, 8). Indeed, data from a limited number of patients indicates
that HIV infects the CNS at early times post-infection (9, 10).
While these studies are not conclusive, they indicate that HIV
has the potential to invade the CNS prior to end stage disease
although the precise timing of the HIV infection into the CNS is
not known.
The ability to undertake careful and controlled studies utiliz-
ing the Rhesus macaque simian immunodeficiency virus (SIV)
infection model has enabled the evaluation of CNS infection
events that cannot be addressed in HIV-infected patients. Indeed,
SIV has been particularly invaluable for investigating the earli-
est post-infection CNS events (11). Four-to-seven days following
intravenous SIV infection, virus can be found within CNS tis-
sues (11) however CNS penetrance at very early times following
mucosal transmission (i.e., oral, vaginal, or rectal) have not been
assessed. Viral DNA can generally be detected throughout the dis-
ease course, although viral RNA is most easily isolated at only
the earliest times post-infection (prior to day 14) suggesting that
viral replication is reduced as the immune response is initiated
(12). The interferon response is induced early in the brain follow-
ing SIV infection (13, 14) and elevated interferon beta expression
can be detected as early as 4 days following an intravenous inoc-
ulation of SIV (13). A concomitant induction of interleukin 10
(IL-10), tumor necrosis factor alpha, and CCL2 expression were
also observed (13). Interestingly, the peak in antiviral response
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in the brain appears to be approximately 7 days post-intravenous
inoculation, and there is some evidence that the viral RNA tran-
scription appears to be somewhat controlled (13) and then reacti-
vates during the chronic times post-infection (13). Finally, despite
the effective control of plasma viremia by current antiretroviral
drug regimens, the CNS represents a site where residual virus
may be maintained resulting in acute or sub-acute neurological
manifestations (15, 16).
A long-standing question in the field of neuroAIDS is the source
of the HIV found in the cerebral spinal fluid (CSF) during chronic
infection. The variants replicating at later times post-intravenous
infection appear to be related to these early species suggesting an
activation of latent virus (12, 17). Some studies analyzing CNS
viral variants following intravenous inoculation have identified
viral variants that appear to be specific to the brain (18) whereas
others did not find evidence for any variants that were particu-
larly brain-tropic (19, 20). One source of these different findings
may be the result of a mixing of the virus produced in the CNS
with virus entering from the peripheral blood circulation (21).
Using highly sensitive nested PCR, we previously observed that SIV
rapidly spreads throughout the systemic lymphoid system within
1–7 days post-oral mucosal transmission (22). Here we investigate
the ability of SIV to spread to the brain in these same macaques
following oral mucosal SIV inoculation and evaluate genetic dif-
ferences of SIV variants in the CNS versus the peripheral tissues
at these earliest time points. Our findings support a model of
rapid SIV spread throughout the body, including the brain, during
the earliest times post-infection. Furthermore, the viral variants
detected in the brain were similar to those found in the peripheral
tissues suggesting that the viral species that cross the mucosal sur-




All animals used in this study were housed at the California
National Primate Research Center (CNPRC) in accordance with
the recommendations of the Association for Assessment and
Accreditation of Laboratory Animal Care International Standards
and with the recommendations in the Guide for the Care and Use
of Laboratory Animals of the National Institutes of Health. These
animal studies were approved by the Institutional Animal Use and
Care Committee at the University of California, Davis, in accor-
dance with NIH guidelines and the recommendations set forth by
the Weatherall Report. Animal housing and care was conducted
according to the Guide for the Care and Use of Laboratory Animals
and the United States Department of Agriculture Animal Welfare
Act. Animals were housed in an air-conditioned facility with an
ambient temperature of 21–25°C and a 12-h light/dark cycle. Each
animal was individually housed during the study period in sus-
pended stainless steel wire-bottom cages and with commercial
primate diet, fresh fruit once daily, and freely available water. All
of the animals in our studies were terminated at specific time
points before progressive disease developed. At predetermined
time points (i.e., 1, 2, 4, 7, and 14 days post-inoculation), the
animals were humanely euthanized using sodium pentobarbital
overdose in accordance with CNPRC and Federal guidelines.
ANIMAL INOCULATIONS AND VIRUS STOCK
A total of 12 animals used in this study were colony-bred rhe-
sus macaques (Macaca mulatta) housed at the CNPRC. Neonatal
macaques ranged from 3 to 15 days of age. Juvenile macaques
ranged from 1.75 to 3.3 years of age. Each macaque was orally
inoculated with two doses of SIVmac251-5/98 each with a 50%
tissue culture infectious doses (TCID50) of 1× 105 (23, 24) to
ensure infection and was administered under ketamine hydrochlo-
ride anesthesia (10 mg/kg) by methods previously described (25).
At the predetermined times post-oral inoculation (i.e., 1, 2, 4,
7, and 14 days post-inoculation), the macaques were humanely
euthanized and numerous lymphatic and non-lymphatic tissues
collected. These analyses were undertaken in both neonate and
juvenile macaques and no distinction in the rate of viral spread
was observed with respect to age. The analysis of non-brain tis-
sues for the presence of SIV following the oral SIV infection of
these same macaques has been previously described in detail (22).
TISSUE COLLECTION AND SAMPLE PROCESSING
At necropsy, lymphoid and brain tissues (i.e., cerebrum and cere-
bellum) were harvested and snap frozen in liquid nitrogen and
stored at −80°C for DNA or RNA isolation. The 2, 4, 7, and
14 days as well as 1 day infected macaques 33711 and 34262 were
not perfused prior to tissue collection. One day infected macaque
33098 underwent perfusion of the brain with sterile 1× phosphate
buffered saline (PBS) to eliminate peripheral blood contamina-
tion. Perfusion was performed while the animal was under deep
ketamine hydrochloride anesthesia. The brain was perfused by
cannulating the left ventricle, clamping the descending aorta and
vena cava, and cutting the right atrium to allow for escape of
the PBS and peripheral blood. A total of 1L of PBS was slowly
pushed through the system by hand in 60 ml increments. The 1 day
infected macaque 33202 underwent a whole body perfusion prior
to tissue collection by the same technique described above, how-
ever, the descending aorta and vena cava were not clamped. Tissues
were preserved by three methods. Samples were snap frozen in liq-
uid nitrogen and stored at −80°C for DNA and RNA isolation.
Tissues were also fixed in Streck’s tissue fixative buffer (Streck
Laboratories, Inc., Omaha, NE, USA) or 10% neutral-buffered
formalin prior to being paraffin embedded.
ASSESSMENT OF SIV gag DNA BY NESTED PCR
Genomic DNA isolation and nested PCR were performed as pre-
viously described (22). The nested PCR approach provided the
sensitivity to repeatedly detect one to five copies of SIV plasmid
DNA. Each DNA sample was tested in 3–20 replicates. Human
and SIV-negative macaque PBMC were used as negative controls.
Further internal controls were established through a re-analysis
of selected tissues that continued to result in a similar number of
PCR positive/negative reactions.
HETERODUPLEX MOBILITY ASSAY ASSESSMENT OF SIV env V1–V2
DIVERSITY
A 590 bp fragment encompassing the V1–V2 regions of SIV was
PCR amplified in triplicate from lymphoid and brain tissues using
a similar nested PCR approach with primer sets that have previ-
ously been described (23). The Env V1–V2 PCR products of the
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triplicate reactions were combined. Then, 20µl of PCR product
were added to 2µl of 10× annealing buffer [1 M NaCl, 100 mM
Tris (pH 7.8), 20 mM Ethylenediaminetetraacetic acid], and the
samples were heated to 100°C for 5 min before rapidly cooling
the reaction on ice. The product was then mixed with 4µl of a
5× loading dye (25% Ficoll, 1% Orange G) and loaded onto a
16% non-denaturing polyacrylamide gel and electrophoresed 2 h
at 250 V. The bands were visualized by ethidium bromide staining.
By heating and rapidly cooling the samples, the two strands of
DNA are rapidly re-annealed and form mismatches if the prod-
uct is not homogenous. Mismatches cause bulges in the DNA that
retard its migration in the gel.
SEQUENCE ANALYSIS OF SIV env V1–V2 REGION
The 590 bp PCR fragment encompassing the V1–V2 regions of
Env was directly sequenced using the Applied Biosystems Big Dye
Terminator 3.1 chemistry and analyzed on an Applied Biosystems
capillary instrument. When double peaks were observed in the
sequences, the nucleotide with the largest peak at the position
was inserted. SIV V1–V2 Env sequences obtained from different
tissues were aligned and a phylogenetic tree using the Neigh-
bor Joining method with 500 bootstrap values was generated by
software MEGA version 4.1 (www.megasoftware.net, Center for
Evolutionary Functional Genomics, Tempe, AZ, USA).
RESULTS
DETECTION OF SIV DNA IN THE BRAIN POST-ORAL INOCULATION
Although SIV has been detected in the brain tissue by day 4–7
following intravenous SIV inoculation (11), the rate at which SIV
enters the brain following mucosal transmission is not known.
To address this question through an evaluation of the oral route
of infection, 12 macaques were orally inoculated with the quasi-
species SIVmac251 as previously described (22, 26). Assessment of
non-CNS tissues of these macaques obtained at days 1, 2, 4, 7, or
14 post-oral SIV administration provided evidence that the oral
cavity and upper GI tract were the likely entry points of the virus
and that the virus rapidly spread to draining and peripheral lym-
phoid tissues (22). Here, CNS tissues (cerebrum and cerebellum)
from these same 12 macaques were assessed using an ultrasensitive
nested (two rounds) PCR approach (sensitivity of one to five copies
of plasmid DNA (22) to detect a 597-bp SIV gag DNA fragment.
As negative controls we included human and uninfected macaque
PBMC DNA in all PCR experiments to demonstrate the speci-
ficity of our SIV gag PCR (previously shown (22). Previously, we
observed in these 12 orally inoculated macaques that SIV could
rapidly spread from the likely entry points, oral mucosa (gingi-
val) and upper esophagus, to the blood and lymphatics within
2–4 dpi (22). Table 1 summarizes the tissues of the head and neck
that were assessed for SIV gag DNA as well as the frequency of
PCR positive results. Using the results of our nested PCR analysis,
we have depicted the approximate anatomical location and color-
coded the results to indicate the relative frequency of SIV gag
PCR positive reactions in each tissue (Figure 1). Dissemination
of the virus to nearly all tissues of the head and neck, including
the cerebrum and cerebellum, is evident at 7 and 14 dpi by the
frequent red (greater than 50% PCR positive) and orange (PCR
positive but at a frequency of less than 50% of the PCR reactions)
colored SIV DNA-positive tissues (Figures 1A,B). Assessment of
cerebrum (larger oval in head) and cerebellum (smaller oval in
head) samples at 1, 2, and 4 days post-infection indicated that the
virus reached these tissues as early as 1–2 dpi (Figures 1C–E). This
rate of spread following oral transmission is similar to that pre-
viously observed following intravenous inoculation (12, 13, 27)
and not influenced by age as both juvenile and neonate macaques
had similar frequencies of SIV DNA PCR positive reactions in
the two brain tissues assessed (Table 1; Figure 1). To rule out
the possibility that residual blood in brain tissues was responsible
for the DNA-positive PCR reactions, we perfused two macaques
(33098 and 33202) at necropsy to remove blood from the brain
tissues. Despite perfusing, SIV nucleic acid was still detected in
the brain tissues of these macaques indicating the virus was likely
residing in cells that had migrated into the CNS tissue. However,
due to the paucity of infected cells, we were unable to identify
the infected cells using in situ hybridization (data not shown).
Indeed, clusters of infected cells could not be identified until 7 dpi
in lymph nodes (22). While the virus appears to be preferentially
detected in the cerebellum at these early time points (seven of
nine macaques assessed between 1 and 4 dpi tested positive for
Table 1 | Detection of SIV nucleic acid in mucosal associated tissues or lymphoid tissues.
J1 N2 N J J J J N J J J
1day 1day 1day 2days 2days 4days 4days 4days 7days 7days 14days
Tissues examined3 33098 33711 34262 30379 30381 29976 30244 33357 30964 30974 30076
Oral mucosa +4 − ++ ++ ++ ++ ++ ++ ++ ++ ++
Lingual tonsil − − − ++ ++ − − + ++ ++ ++
Palatine tonsil na5 − − + ++ ++ ++ ++ na na na
Cerebrum − − + ++ − − + − + ++ +
Cerebellum + − + + + + + + − ++ +
PBMC post-infection − + − + + + + ++ ++ ++ na
1J, juvenile; 2N, neonate.
3All tissues were assessed in carefully controlled nested PCR reactions for SIV gag DNA.
4Indicates number of positive reactions to the total number of replicates tested.
5“na” indicates tissues were not assessed.
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FIGURE 1 | Anatomic distribution of SIV gag DNA-positive tissues of
the head. (A–E)Tissues are depicted in their general anatomical position.
(A,B,D) Juvenile macaques. (C) 29976 and 30244 are juvenile macaques
and 33357 is a neonate. (E) Macaques 33098 and 33202 are juveniles and
33711 and 34262 are neonates. To minimize the possibility that SIV in the
blood of tissues would be detected by PCR, the head of macaque 33098
and the whole body of 33202 were perfused with PBS prior to collecting
tissues. Despite perfusing these animals, SIV gag DNA was detected in the
brain. Results are based on the number of SIV gag DNA-positive reactions
with a minimum of three reactions for non-brain tissues and seven reactions
for cerebrum and cerebellum. Tissues are depicted as follows: red, 50% or
more of the PCR reactions were positive; orange, less than 50% of PCR
reactions positive; blue, no PCR reactions positive; gray, tissues not
available.
SIV DNA in the cerebellum compared to only four of nine testing
SIV DNA-positive in the cerebrum), the results of a Fisher’s exact
test were not significant (p= 0.3348). Importantly, SIV DNA in the
blood was not detected at 1 day post-infection and was detected in
less than 50% of PCR reactions performed at 2 and 4 days post-
infection. In contrast to SIV DNA, detection of SIV RNA is more
difficult and in our previous study of these same macaques we
were unable to reliably detect SIV RNA in lymphoid tissues prior
to 4–7 days post-infection (22). Similarly, attempts to amplify SIV
RNA by traditional or quantitative RT-PCR from brain tissues
of these 12 macaques were also unsuccessful (data not shown).
These findings are the first to indicate that SIV can gain access
to the CNS very early (by 1–2 dpi) following non-traumatic oral
mucosal administration of virus.
SYSTEMIC AND CNS VIRAL DIVERSITY ASSESSMENT
Previous studies utilizing intravenous transmission have assessed
whether tissue-specific viral sequestration occurs, and although
sequestration can be observed in some studies, others have
observed a more random distribution of variants in different
tissues (18–20, 28). Here, the ability of the virus to gain access to
the brain tissues within 1–2 days post-mucosal transmission raises
the question as to whether the variants entering the brain at these
early time points are distinct from those found in the periphery.
To evaluate this question, a 590 bp DNA fragment encompassing
the V1–V2 regions of SIV was PCR amplified from lymphoid and
brain tissues and the diversity assessed by heteroduplex mobil-
ity assay (HMA) analysis. For DNA fragments of equal length,
HMA requires a minimum of 1–2% mismatches in the sequences
to detect heteroduplexes (29, 30). Utilizing HMA, two bands pre-
dominated in nearly all tissues assessed including the cerebrum
and cerebellum indicating viral diversity was similar in all tissues
assessed (Figure 2). To further support these findings, we per-
formed sequence analysis of the 590 bpV1–V2 fragment. Neighbor
joining phylogenetic analysis indicated viral sequences detected
in cerebrum and cerebellum could also be found in other tissues
(Figure 3). Taken together, these data suggest that once SIV crosses
the mucosal barrier, the virus can spread quickly to all tissues of the
body including the brain with no evidence for any tissue-specific
viral sequestration.
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FIGURE 2 | Heteroduplex mobility assay of viral DNA from lymphoid,
mucosal, and brain tissues. The PCR amplified SIV envelope gene
spanning the V1–V2 region was heated and rapidly re-annealed prior to
separation by electrophoresis through a non-denaturing polyacrylamide gel
and visualized by ethidium bromide staining. Two heteroduplex bands
predominated in the majority of tissues examined indicating a limited viral
diversity.
DISCUSSION
Here we undertook a high dose oral administration of SIV to eval-
uate the rate at which SIV can be observed within CNS tissues
following an oral infection. This oral infection route is relevant
with regard to both mother-to-child transmission of HIV when
virus is present within the breast milk (31) as well as oral-genital
transmission when virus is present in semen (32). Our studies
found SIV in brain tissues by 1–2 days post-inoculation indicating
a rapid spread of the virus following oral transmission. We also
determined that brain variants are similar to variants replicating in
other tissues of the body and therefore no evidence for viral com-
partmentalization was observed in our study at these very early
time points. It will be interesting to determine in future studies
whether lower dose SIV mucosal inoculations at other mucosal
sites result in a similar rate of spread throughout the lymphatics
and into the CNS and whether this affects viral diversity in the
different tissue compartments.
The use of saline perfusions to remove residual blood within the
brain provides evidence that the SIV was present within the CNS
tissue and not in the blood. Indeed, we were not able to detect SIV
DNA in blood at 1 day post-infection and less than 50% of PCR
reactions performed at 2 and 4 days post-infection were positive
for SIV DNA. The extremely low levels of SIV DNA in the blood
during the first 4 days post-infection and the observation that per-
fusion did not change the detection of SIV DNA in these tissues
supports the conclusion that SIV DNA was within the CNS.
Our studies also tried to evaluate whether different tissue
sections (i.e., cerebrum versus cerebellum) of the brain contained
higher or lower amounts of SIV. Although our study did not
observe a significant difference in the detection of SIV nucleic acid
between the cerebrum and cerebellum, another study did find a
FIGURE 3 | Phylogenetic analysis of SIV EnvV1–V2 regions in
lymphoid and non-lymphoid tissues following oral inoculation. The
viral diversity within the first 7 days post-oral transmission of SIV results
indicates the SIV env V1–V2 sequences in the cerebrum and cerebellum are
closely related to sequences found in other lymphoid tissues.
preferential infection and intrinsic sensitivity to damage of par-
ticular areas of the brain using the SIV model (33). Furthermore,
a detailed post-mortem assessment of HIV viral RNA levels in
numerous areas of the brain indicated extensive intra- and inter-
individual variability ranging from undetectable to greater than
107 copies per gram of tissue (34). Our inability to observe any
significant differences in the different tissues of the brain may be
due to the early time points analyzed here in contrast to the more
chronic samples evaluated in the other studies.
The limited viral diversity in the brain as well as other tissues of
the body observed in this study indicates the bottleneck the oral/GI
tract mucosal barrier imposes on the viral quasispecies. This is in
agreement with previous studies demonstrating that vaginal trans-
mission of SIV also results in lower viral diversity compared to IV
inoculation (23, 35). Moreover, the rapid dissemination of SIV
following oral inoculation is similar to the dissemination of SIV
observed following vaginal inoculation (36). Indeed, as early as
1 day post-vaginal inoculation systemic lymphoid tissues as well
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as tissues of the intestinal tract have been found to contain viral
RNA (36). Miller et al. did not however assess tissues of the CNS
for viral presence at these very early time points (36). Interest-
ingly, following oral or vaginal inoculation, viral RNA or DNA
was not detectable in the plasma within the first 2 days post-
inoculation suggesting the virus was trafficking to the different
tissue compartments via the lymphatics.
The difficulties we faced to identify the cell types infected in
these brains is likely due to a paucity of infected cells. However,
using autologous dye-labeled lymphocytes Clay et al. have demon-
strated that during acute SIV infection the elevated concentrations
of CCL2 and CXCL9 in the CSF recruits monocytes from the blood
into the choroid plexus of the brain (37). This may serve as a portal
of entry for SIV, and likely HIV, during acute infection. However,
it remains unknown as to whether these monocytes are produc-
tively infected or whether they are a conduit permitting infection
of potential target cells in the brain.
The early penetration of virus into the CNS displayed here
suggests that neural injury eventually resulting in HIV-associated
neurocognitive complications and AIDS-associated dementia has
the potential to begin shortly after infection. Indeed, one study in
macaques demonstrated that neurocognitive changes can be mea-
sured within 3 months post-SIV infection and persist through-
out infection (38). As the life expectancies among HIV-infected
patients increase and as the population ages, neurocognitive
impairments become a growing concern. Furthermore, current
antiretroviral regimens do not appear to be able to effectively
control viral replication in the CNS in all cases resulting in
a potential source of residual virus in the CNS (16, 27, 39).
This would suggest that early treatment with neuroprotective
drugs might protect HIV-infected individuals from neurocogni-
tive impairments or at least drastically slow this process down. Two
very interesting neuroprotective molecules are the endogenous
neurosteroids, dehydroepiandrosterone, and allopregnanolone,
that not only have neuroprotective effects [reviewed in (40)], but
also have antiviral properties (41–43).
There appears to be a general consensus that the infected cell
type in the CNS is macrophage-like, although the exact subset(s)
remains less clear [reviewed in (44)]. Estimates of the life span of
perivascular macrophages, considered a target of HIV and SIV in
the brain, range from days to weeks or longer according to one rhe-
sus macaque study (45). The varying degrees of CNS penetrance
of antiretrovirals (46) and the natural differences in turn-over of
infected cells make it difficult to determine whether HIV can be
completely eradicated from this tissue compartment. Early anti-
retroviral treatment, and possibly adjunctive treatments designed
to specifically help the CNS, may help ameliorate CNS disease.
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